Fig. 1.

Nsd2 is dispensable for Treg development and function. a Flow cytometric analysis of the Treg (CD4⁺CD25⁺YFP⁺) percentage and number in the spleen (Spl) and peripheral lymph nodes (pLNs, pooled from inguinal and axillary LNs) of 8-week-old Nsd2^{Treg WT} and Nsd2^{Treg KO} mice. n = 7. b Flow cytometric analysis of the frequencies of naïve (CD44^loCD62L^hi) and memory-like (CD44^hiCD62L^lo) CD4⁺ and CD8⁺ T cells in total splenocytes from 8-week-old Nsd2^{Treg WT} and Nsd2^{Treg KO} mice. n = 7. c Representative images of hematoxylin and eosin staining of the indicated tissues from Nsd2^{Treg WT} and Nsd2^{Treg KO} mice at the age of 4 months. Scale bars, 200 µm. d In vitro Treg suppression assay measuring the percentage of divided CD4⁺ T cells (Teff) by CFSE dilution after coculture for 3 days with the indicated ratio of Teff/Treg cells. Data are representative of two experiments. e Flow cytometric analysis of YFP⁺ Tregs among CD4⁺ cells infiltrating the CNS of Nsd2^{Treg WT} and Nsd2^{Treg KO} mice. n = 6. f Flow cytometric analysis of IFNγ⁺, IL-17A⁺, and IFNγ⁺IL-17A⁺ cells among CD4⁺ cells infiltrating the CNS of Nsd2^{Treg WT} and Nsd2^{Treg KO} mice. n = 6. g The clinical severity of EAE in Nsd2^{Treg WT} and Nsd2^{Treg KO} mice was monitored for 22 days after immunization with the MOG peptide. n = 12. ns not significant